a

argenx

897 employees

arGEN-X offers a platform for antibody lead choice that supports the discovery of human antibody therapeutics.

Investor insights

Sectors invested in

biotechnology1
Medical1
Marketing1
Biotechnology1
rHuPH201
subcutaneous biologics1
hyaluronidase1

Funding rounds participated in

$30M sweet spot round size

Most of their 1 investments are in rounds between $30M and $30M

Basic info

Industry

biotechnology research

Sectors

Biotechnology
high-risk myelodysplastic syndromes
Rare Diseases
Oncology
Myasthenia Gravis
Acute Myeloid Leukemia
Pemphigus Vulgaris
Clinical Trials
Therapeutics
Immunotherapy
chronic inflammatory demyelinating polyneuropathy
Immunology
Immune Thrombocytopenia
Antibody based medicines
Autoimmune diseases

Date founded

2008

Investments made

H

Halozyme Therapeutics, Inc. raised $30M on February 6, 2019

Investors: argenx

Funding rounds raised

Total raised

$44M

from 19 investors over 19 rounds

a

argenx raised $33M on June 3, 2016

Investors: Burrage Capital Management, Aquila Capital, DAFNA Capital Management, LLC and MPM Capital

a

argenx raised $44M on December 1, 2011

Investors: Erasmus MC Biomedical Fund, LSP (Life Sciences Partners), Omnes, OrbiMed Advisors, Seventure Partners and Forbion

a

argenx raised $4.5M on February 11, 2010

Investors: BGV (BioGeneration Ventures), Thuja Capital, Omnes, EQT Life Sciences, Erasmus MC Biomedical Fund and Forbion

a

argenx raised $14M on September 10, 2009

Investors: Erasmus MC Biomedical Fund, BGV (BioGeneration Ventures) and Forbion

FAQ